Xinhua Pharmaceutical announced that in April 2025, the company submitted the marketing license registration application data for sacubatl valsartan tablets to the Drug Evaluation Center of the State Drug Administration and was accepted; in October 2026, it obtained the “Drug Registration Certificate” approved and issued by the State Drug Administration. The review concluded that registration was approved.

Xinhua Pharmaceutical announced that in April 2025, the company submitted the marketing license registration application data for sacubatl valsartan tablets to the Drug Evaluation Center of the State Drug Administration and was accepted; in October 2026, it obtained the “Drug Registration Certificate” approved and issued by the State Drug Administration. The review concluded that registration was approved.